Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Verapamil vs Steroid to Prevent Keloid Recurrence
NCT01720056 · The University of Western Australia · PHASE4 · terminated · last registry update 2015-06-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Objective of study achieved after interim analysis.” | – | Registry record, The University of Western Australia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CACNA1C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-06-08Results posted on the registry: Food and Drug Administration (FDA), Dofetilide + Mexiletine (NCT02308748)
- 2016-05-13Phase 3 first posted: Meshalkin Research Institute of Pathology of Circulation, Metoprolol + Verapamil (NCT02772354)
- 2016-02-19Results posted on the registry: University of Utah, dronedarone + Placebo (NCT01182376)
- 2015-12-18Also stopped (terminated): Pennington Biomedical Research Center, Diltiazem (NCT01021176)
- 2015-12-01Phase 3 first posted: Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2015-11-03Results posted on the registry: Nazarbayev University, Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin (NCT02503865)
- 2015-09-23Phase 3 first posted: University Hospital, Strasbourg, France, Urapidil + Nicardipine (NCT02558023)
- 2015-09-07Results posted on the registry: University of Minnesota, nicardipine (NCT00415610)
- 2015-05-21Results posted on the registry: Food and Drug Administration (FDA), Ranolazine + Dofetilide (NCT01873950)
- 2015-04-07Results posted on the registry: Brigham and Women's Hospital, Diltiazem + Placebo (NCT00319982)
- 2015-02-27Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Lisinopril + Telmisartan (NCT00283686)
- 2015-01-26Results posted on the registry: Daiichi Sankyo Co., Ltd., DU-176b 15mg + DU-176b 30mg (NCT01857622)
- 2015-01-09Also stopped (withdrawn): Ottawa Hospital Research Institute, Amlodipine + Diltiazem (NCT01549496)
- 2015-01-08Also stopped (withdrawn): University of Michigan, Esmolol (NCT01232400)
- 2014-12-11Results posted on the registry: The Cleveland Clinic, nicardipine intravenous + Labetalol (NCT00765648)
- 2014-09-15Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Anti-hyperglycemic Agents + Anti-hypertensive Agents (NCT00000620)
- 2014-09-05Results posted on the registry: Calosyn Pharma, Inc., Verapamil + Placebo (NCT01645709)
- 2014-09-05Also stopped (terminated): Calosyn Pharma, Inc., Verapamil + Placebo (NCT01645709)
- 2014-08-29Results posted on the registry: University of Florida, Nicardipine hydrochloride + Preservative-free normal saline (NCT01810302)
- 2014-08-29Also stopped (terminated): University of Florida, Nicardipine hydrochloride + Preservative-free normal saline (NCT01810302)
- 2014-08-29Results posted on the registry: Northwestern University, Nicardipine + Esmolol (NCT01951950)
- 2014-08-19Results posted on the registry: The Medicines Company, Clevidipine + Standard of Care IV antihypertensive (NCT00803634)
- 2014-08-06Also stopped (terminated): Sanofi, Dronedarone + Placebo (for dronedarone) (NCT01026090)
- 2014-08-01Also stopped (terminated): Duke University, Nicardipine + 0.9% saline (NCT00508118)
- 2014-07-01Results posted on the registry: S.L.A. Pharma AG, Diltiazem hydrochloride 4% cream + Diltiazem hydrochloride 2% cream (NCT01217515)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision